Company overview
Sonoma Biotherapeutics is a clinical-stage biotech company developing engineered regulatory T cell (Treg) therapies and effector T cell-modulating biologics to restore immune balance in autoimmune and inflammatory diseases. Their lead program, SBT-77-7101, is an autologous CAR-Treg therapy in Phase 1/1b for rheumatoid arthritis and hidradenitis suppurativa. The platform leverages proprietary manufacturing to isolate, expand, and enhance patient-derived Tregs for targeted immune modulation and potential disease cures.
Sonoma Biotherapeutics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include treg cell therapy, autoimmune disease treatment, car-treg, rheumatoid arthritis therapy, immune modulation biotech.
Structured facts
- Website
- https://sonomabio.com
- Markets served
- United States & Americas
- Keywords
- treg cell therapy, autoimmune disease treatment, car-treg, rheumatoid arthritis therapy, immune modulation biotech
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are Sonoma Biotherapeutics' key therapeutic programs?
- SBT-77-7101 is an autologous CAR-Treg therapy in Phase 1/1b for rheumatoid arthritis and hidradenitis suppurativa. SBT-11-5301 is a biologic that eliminates activated effector T cells, with Phase 1 completed in healthy volunteers and plans for combination trials.
- What is their Treg cell therapy platform?
- The platform engineers patient-derived Tregs through proprietary processes for selection, expansion, specificity, potency, stability, and persistence, aiming for one-time treatments that modulate immune responses and repair tissue in autoimmune diseases.
- What is the clinical and regulatory status of their pipeline?
- SBT-77-7101 is advancing in Phase 1/1b clinical trials. SBT-11-5301 has completed Phase 1 in healthy volunteers, with future combination studies planned. They partner with Regeneron on select Treg programs.
Related editorial coverage
- Nkarta Receives FDA Approval for Outpatient NKX019 Dosing in Autoimmune Disease Treatment
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
